Email: paolo.colombo@unipr.it
President of Interuniversity Consortium on Innovative Pharmaceutical Technologies TEFARCO Innova, c/o Department of Pharmacy, Parma, Italy
Keywords of expertise: 1. Particle engineering, 2. DPI Device development, 3. In vitro assessment of respirability, 4. Spray drying technique for dry particle manufacturing
Golden Paragraph: Paolo Colombo primary research activity in inhalation is the design and development of novel inhalation products with a special focus on DPI. The primary goal is the search of a safe and convenient administration of large doses of drug in particular antiinfectives, to treat lung microbial and viral dependent diseases. In this regard the recent pubblications on cystic fibrosis Pseudomonas infection treatment by aminoglycosides drive to an approval for orphan designation of a powder of amikacin or tobramycin. The product is administered with a new device for powder inhalation capable to accept a dose of powder larger that 100 mg. We found a novel system and technique capable to regulate the powder emission in order not to suffucate the patient during inhalation since the large dose is emitted in small portions. This allows the complete deposition of the drug in the lung area defined by the aerodynamic size distribution of the aerosol particles.